Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromatin licensing and DNA replication factor 1 (CDT1)
- Target
- CDT1
- Molecular classification
- Licensing factor, DNA replication initiation factor, Pre-replication complex component, Other (occasionally grouped with cell cycle regulation proteins due to function)
01
Overview
Chromatin licensing and DNA replication factor 1 (CDT1) is a key protein encoded by the *CDT1* gene that regulates DNA replication. It is an essential licensing factor for the assembly of pre-replication complexes at replication origins, ensuring that DNA replication occurs only once per cell cycle. CDT1 cooperates with CDC6 and the origin recognition complex during the G1 phase; its activity is negatively regulated after initiation by inhibitory proteins such as Geminin and by targeted degradation. Dysregulation of CDT1 is associated with genomic instability, cancer, and developmental syndromes such as Meier-Gorlin syndrome.
- Other names
- DNA replication factor Cdt1DUPRIS2Double parked homologDouble parked, Drosophila, homolog ofCDT1_HUMAN
02
Mechanism of action
Not directly targeted by approved drugs. Possible mechanisms under exploration: inhibition of replication licensing to prevent uncontrolled cell proliferation in cancer models, or modulating interaction with Geminin (endogenous inhibitor).
03
Biological functions
DNA replication licensing — ensures that DNA is replicated only once per cell cycleAssembly of pre-replication complexes (pre-RC) during G1 phaseRegulation of cell cycle progression
04
Disease associations
Cancer — overexpression or dysregulation can cause genomic instability and contribute to cancer formationMeier-Gorlin syndrome — germline mutations cause dwarfism and developmental anomaliesGenomic instability syndromes
05
Safety considerations
Inhibition or dysregulation of CDT1 activity may result in genetic instability, chromosomal aberrations, and cell deathOverexpression causes DNA rereplication and genomic damage
06
Interacting drugs
No approved drugs directly target CDT1; however, CDT1 has been studied as a potential cancer target, and pre-replication complex inhibitors or modulators of DNA replication licensing are experimental areas of research.
1 more in the full profile.
07
Biomarkers
Elevated CDT1 expression may serve as a biomarker for genomic instability or cancer risk in some tumor typesDiagnostic marker for Meier-Gorlin syndrome mutations
Beyond the preview
Go deeper on Chromatin licensing and DNA replication factor 1 (CDT1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chromatin licensing and DNA replication factor 1 (CDT1).